Official Title
An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
Brief Summary

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

Detailed Description

This is a study to collect information on adverse events (side effects) that occur during treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (CRPC). To participate in this study patients must have failed 1 or 2 chemotherapy regimens (1 of which contained a taxane such as docetaxel), reside in an area where abiraterone acetate is not yet available through local healthcare providers, and not be eligible for enrollment in any other ongoing clinical research study of abiraterone acetate. CRPC is progressive form of prostate cancer where the cancer cells become resistant to hormonal therapies that are designed to block the release or uptake of testosterone and the cancer cells metastasize (ie, spread to other parts of the body). Abiraterone acetate (referred to as abiraterone) is a drug currently under development for use in treating men with CRPC. Patients will be treated with abiraterone and prednisone daily until progression of clinical disease (ie, includes signs of clinical disease progression and/or clinical disease progression confirmed by radiographic and prostate-specific antigen [PSA] test results). Other reasons for discontinuation of treatment may include adverse events reported, initiation of other anticancer therapies, or the patient's inability to comply with dosing instructions. Patients will be followed for 30 days after the discontinuation of treatment with abiraterone acetate. Patients will take four 250-mg tablets of abiraterone orally at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day. Patients will also take 5 mg of oral prednisone, twice daily. Each treatment cycle consists of 28 days and patients will take abiraterone continually on a daily basis until disease progression is observed at which time abiraterone will be discontinued and the dose of prednisone reduced if clinically indicated.

Approved for marketing
Prostate Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male

Drug: Abiraterone Acetate
Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.

Drug: Prednisone\Prednisolone
Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).

Eligibility Criteria

Inclusion Criteria:

- Confirmed prostate cancer

- Prostate cancer progression after previous chemotherapy as assessed by the investigator

- Received at least 1 but not more than 2 chemotherapy regimens for metastatic CRPC (at least one regimen must have contained a taxane such as docetaxel)

- Serum testosterone of less than 50ng/dL (less than 2.0 nM)

- Eastern Cooperative Oncology Group (ECOG) performance status of =160 mmHg or diastolic blood pressure >=95 mmHg)

- History of gastrointestinal disorders that may interfere with the absorption of the study drug or history of pituitary or adrenal dysfunction

- Known brain metastasis (ie, spread of cancer to the brain)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 99 Years
Countries
Australia
Brazil
Canada
Colombia
Croatia
Czech Republic
Denmark
Greece
Hong Kong
Hungary
Indonesia
Korea, Republic of
Malaysia
Mexico
New Zealand
Poland
Puerto Rico
Romania
Russian Federation
Singapore
Spain
Taiwan
Thailand
United States
Locations

Birmingham, Alabama,

Mobile, Alabama,

Chandler, Arizona,

Scottsdale, Arizona,

Tucson, Arizona,

Anaheim, California,

Bellflower, California,

Berkeley, California,

Beverly Hills, California,

Duarte, California,

Encinitas, California,

Glendale, California,

Greenbrae, California,

La Jolla, California,

Laguna Hills, California,

Long Beach, California,

Los Angeles, California,

Marina Del Rey, California,

Rancho Mirage, California,

San Diego, California,

San Francisco, California,

Santa Rosa, California,

Stanford, California,

Aurora, Colorado,

Colorado Springs, Colorado,

Denver, Colorado,

Fort Collins, Colorado,

Littleton, Colorado,

Hartford, Connecticut,

Manchester, Connecticut,

New Britain, Connecticut,

Norwalk, Connecticut,

Norwich, Connecticut,

Southington, Connecticut,

Stamford, Connecticut,

Torrington, Connecticut,

Trumball, Connecticut,

Washington, District of Columbia,

Boca Raton, Florida,

Fort Lauderdale, Florida,

Fort Myers, Florida,

Gainesville, Florida,

Miami, Florida,

Ocala, Florida,

Orlando, Florida,

Palm Beach Gardens, Florida,

Port Saint Lucie, Florida,

South Miami, Florida,

Atlanta, Georgia,

Savannah, Georgia,

Honolulu, Hawaii,

Post Falls, Idaho,

Chicago, Illinois,

Decatur, Illinois,

Harvey, Illinois,

Niles, Illinois,

Peoria, Illinois,

Urbana, Illinois,

Fort Wayne, Indiana,

Lafayette, Indiana,

Merrillville, Indiana,

Muncie, Indiana,

Bettendorf, Iowa,

Westwood, Kansas,

Lexington, Kentucky,

Louisville, Kentucky,

Marrero, Louisiana,

New Orleans, Louisiana,

Bangor, Maine,

Scarborough, Maine,

Easton, Maryland,

Rockville, Maryland,

Boston, Massachusetts,

Worcester, Massachusetts,

Dearborn, Michigan,

Detroit, Michigan,

Grand Rapids, Michigan,

Lansing, Michigan,

Rochester, Minnesota,

Saint Louis Park, Minnesota,

St. Joseph, Missouri,

Billings, Montana,

Omaha, Nebraska,

Las Vegas, Nevada,

Hooksett, New Hampshire,

Portsmouth, New Hampshire,

Cherry Hill, New Jersey,

Hackensack, New Jersey,

Livingston, New Jersey,

Morristown, New Jersey,

New Brunswick, New Jersey,

Paramus, New Jersey,

Los Alamos, New Mexico,

Albany, New York,

Binghamton, New York,

Bronx, New York,

Brooklyn, New York,

Buffalo, New York,

Cooperstown, New York,

Dunkirk, New York,

East Setauket, New York,

East Syracuse, New York,

Fresh Meadows, New York,

Glens Falls, New York,

Mt. Kisco, New York,

New Hyde Park, New York,

New York, New York,

Rochester, New York,

Stony Brook, New York,

Syracuse, New York,

Chapel Hill, North Carolina,

Charlotte, North Carolina,

Durham, North Carolina,

Greenville, North Carolina,

Hendersonville, North Carolina,

High Point, North Carolina,

Huntersville, North Carolina,

Pinehurst, North Carolina,

Raleigh, North Carolina,

Cincinnati, Ohio,

Cleveland, Ohio,

Columbus, Ohio,

Dayton, Ohio,

Elyria, Ohio,

Massillon, Ohio,

Middletown, Ohio,

Sandusky, Ohio,

Bethany, Oklahoma,

Oklahoma City, Oklahoma,

Portland, Oregon,

Allentown, Pennsylvania,

Philadelphia, Pennsylvania,

West Reading, Pennsylvania,

Providence, Rhode Island,

Charleston, South Carolina,

Columbia, South Carolina,

Greenville, South Carolina,

Myrtle Beach, South Carolina,

Bristol, Tennessee,

Chattanooga, Tennessee,

Memphis, Tennessee,

Nashville, Tennessee,

Austin, Texas,

Corpus Christi, Texas,

Dallas, Texas,

Galveston, Texas,

Houston, Texas,

San Antonio, Texas,

Temple, Texas,

The Woodlands, Texas,

Salt Lake City, Utah,

Burlington, Vermont,

Hampton, Virginia,

Newport News, Virginia,

Norfolk, Virginia,

Seattle, Washington,

Milwaukee, Wisconsin,

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Study Director
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT Number
Keywords
Metastatic Castration-Resistant Prostate Cancer (CRPC)
Abiraterone Acetate
MeSH Terms
Prostatic Neoplasms
Neoplasms
Urogenital Neoplasms
Genital Neoplasms, Male
Prednisone
Prednisolone
Abiraterone Acetate